Minnesota Oncology

Rectal Cancer News

TAS-102 Improves Survival in Advanced Colorectal Cancer (July 9, 2014)

Researchers recently reported that the new combination agent TAS-102 improves overall survival in patients whose metastatic colorectal cancer is refractory to standard therapies. These results were recently reported at the ESMO 16th World Congress on... Continue Reading

Chemotherapy Regimens paired with Avastin or Erbitux Extended Survival for Patients with Metastatic Colorectal Cancer (June 20, 2014)

In a plenary session of the American Society of Clinical Oncology (ASCO) meeting in Chicago, researchers reported that treatment of metastatic colorectal cancer with Avastin® (bevacizumab) or Erbitux® (cetuximab) and standard chemotherapy (FOLFOX or... Continue Reading

FOLFOX Improves Disease-Free Survival in Stage II and III Rectal Cancer Patients (June 11, 2014)

Researchers at the University of Ulsan College of Medicine in South Korea reported that treatment with the FOLFOX chemotherapy regimen in rectal cancer patients improved 3-year disease-free survival over a standard chemotherapy of 5-FU/leucovorin. The... Continue Reading

Predicting SIR-Spheres® microspheres Treatment Outcomes for Metastatic Colorectal Cancer (March 5, 2014)

Pre-treatment laboratory tests may play a key role in predicting patient outcomes prior to selective internal radiation therapy for metastatic colorectal cancer, while a new modeling technology for enhancing delivery of treatment could improve treatment... Continue Reading

Stool Test Spots Most Colon Cancers (February 19, 2014)

A stool test known as the fecal immunochemical test (FIT) is accurate in diagnosing most colorectal cancers, according to a meta-analysis published in the Annals of Internal Medicine. Screening is crucial for the prevention and early detection of colorectal... Continue Reading

Colorectal Cancer Screening Works Over Long-Term (October 4, 2013)

The results of a study published in the New England Journal of Medicine, suggest that it pays to follow colorectal cancer screening recommendations—and people who do follow the guidelines are less likely to develop colon cancer than people who do not. Colorectal... Continue Reading

End-of-Life Care Remains Aggressive, Despite Patient Wishes (September 16, 2013)

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact, elderly patients with advanced cancer often receive... Continue Reading

Low-Dose Aspirin Reduces Colon Cancer Risk in Women (August 7, 2013)

Women who take a low-dose aspirin every other day have a reduced risk of colon cancer, according to the results of a study published in the Annals of Internal Medicine—however, the benefit carries with it a risk of gastrointestinal bleeding.[1] Colorectal... Continue Reading

Biomarker Could Potentially Help Detect Colorectal Cancer (July 29, 2013)

Blood levels of miR-21, a piece of DNA known as microRNA, could serve as a promising biomarker for the early detection and prognosis of colorectal cancer, according to the results of a study published in the Journal of the National Cancer Institute. Colorectal... Continue Reading

Aspirin’s Preventive Effect for Colorectal Cancer Linked to Genotype (July 24, 2013)

Aspirin’s preventive effect for colorectal cancer may be limited to tumors without a genetic mutation known as BRAF, according to the results of a study published in the Journal of the American Medical Association.[1] Colorectal cancer remains the... Continue Reading

Latest Rectal Cancer News By Stage


Recurrent/Relapsed Rectal Cancer

TAS-102 Improves Survival in Advanced Colorectal Cancer (July 9, 2014)

Researchers recently reported that the new combination agent TAS-102 improves overall survival in patients whose metastatic colorectal cancer is refractory to standard therapies. These results were recently reported at the ESMO 16th World Congress on... Continue Reading

Chemotherapy Regimens paired with Avastin or Erbitux Extended Survival for Patients with Metastatic Colorectal Cancer (June 20, 2014)

In a plenary session of the American Society of Clinical Oncology (ASCO) meeting in Chicago, researchers reported that treatment of metastatic colorectal cancer with Avastin® (bevacizumab) or Erbitux® (cetuximab) and standard chemotherapy (FOLFOX or... Continue Reading

Predicting SIR-Spheres® microspheres Treatment Outcomes for Metastatic Colorectal Cancer (March 5, 2014)

Pre-treatment laboratory tests may play a key role in predicting patient outcomes prior to selective internal radiation therapy for metastatic colorectal cancer, while a new modeling technology for enhancing delivery of treatment could improve treatment... Continue Reading

Erbitux Plus Chemo Boosts Survival in Patients with Colorectal Cancer and Liver Metastases (May 29, 2013)

Adding Erbitux® (cetuximab) to standard chemotherapy might allow some patients with colorectal cancer and inoperable liver metastases to undergo successful surgical resection of the liver metastasis, according to the results of a study published in the Journal... Continue Reading

Aspirin May Prolong Life in PIK3CA-Mutated Colorectal Cancers (November 6, 2012)

Daily aspirin use improves survival among patients with mutated-PIK3CA colorectal cancer, according to the results of a study published in the New England Journal of Medicine. Colorectal cancer remains the second leading cause of cancer-related death... Continue Reading

More Recurrent/Relapsed Rectal Cancer

Screening/Prevention Rectal Cancer

Stool Test Spots Most Colon Cancers (February 19, 2014)

A stool test known as the fecal immunochemical test (FIT) is accurate in diagnosing most colorectal cancers, according to a meta-analysis published in the Annals of Internal Medicine. Screening is crucial for the prevention and early detection of colorectal... Continue Reading

Colorectal Cancer Screening Works Over Long-Term (October 4, 2013)

The results of a study published in the New England Journal of Medicine, suggest that it pays to follow colorectal cancer screening recommendations—and people who do follow the guidelines are less likely to develop colon cancer than people who do not. Colorectal... Continue Reading

Low-Dose Aspirin Reduces Colon Cancer Risk in Women (August 7, 2013)

Women who take a low-dose aspirin every other day have a reduced risk of colon cancer, according to the results of a study published in the Annals of Internal Medicine—however, the benefit carries with it a risk of gastrointestinal bleeding.[1] Colorectal... Continue Reading

Biomarker Could Potentially Help Detect Colorectal Cancer (July 29, 2013)

Blood levels of miR-21, a piece of DNA known as microRNA, could serve as a promising biomarker for the early detection and prognosis of colorectal cancer, according to the results of a study published in the Journal of the National Cancer Institute. Colorectal... Continue Reading

Aspirin’s Preventive Effect for Colorectal Cancer Linked to Genotype (July 24, 2013)

Aspirin’s preventive effect for colorectal cancer may be limited to tumors without a genetic mutation known as BRAF, according to the results of a study published in the Journal of the American Medical Association.[1] Colorectal cancer remains the... Continue Reading

More Screening/Prevention Rectal Cancer

Stage IV Rectal Cancer

TAS-102 Improves Survival in Advanced Colorectal Cancer (July 9, 2014)

Researchers recently reported that the new combination agent TAS-102 improves overall survival in patients whose metastatic colorectal cancer is refractory to standard therapies. These results were recently reported at the ESMO 16th World Congress on... Continue Reading

Chemotherapy Regimens paired with Avastin or Erbitux Extended Survival for Patients with Metastatic Colorectal Cancer (June 20, 2014)

In a plenary session of the American Society of Clinical Oncology (ASCO) meeting in Chicago, researchers reported that treatment of metastatic colorectal cancer with Avastin® (bevacizumab) or Erbitux® (cetuximab) and standard chemotherapy (FOLFOX or... Continue Reading

Predicting SIR-Spheres® microspheres Treatment Outcomes for Metastatic Colorectal Cancer (March 5, 2014)

Pre-treatment laboratory tests may play a key role in predicting patient outcomes prior to selective internal radiation therapy for metastatic colorectal cancer, while a new modeling technology for enhancing delivery of treatment could improve treatment... Continue Reading

Erbitux Plus Chemo Boosts Survival in Patients with Colorectal Cancer and Liver Metastases (May 29, 2013)

Adding Erbitux® (cetuximab) to standard chemotherapy might allow some patients with colorectal cancer and inoperable liver metastases to undergo successful surgical resection of the liver metastasis, according to the results of a study published in the Journal... Continue Reading

Aspirin May Prolong Life in PIK3CA-Mutated Colorectal Cancers (November 6, 2012)

Daily aspirin use improves survival among patients with mutated-PIK3CA colorectal cancer, according to the results of a study published in the New England Journal of Medicine. Colorectal cancer remains the second leading cause of cancer-related death... Continue Reading

More Stage IV Rectal Cancer

Stages I-III Rectal Cancer

FOLFOX Improves Disease-Free Survival in Stage II and III Rectal Cancer Patients (June 11, 2014)

Researchers at the University of Ulsan College of Medicine in South Korea reported that treatment with the FOLFOX chemotherapy regimen in rectal cancer patients improved 3-year disease-free survival over a standard chemotherapy of 5-FU/leucovorin. The... Continue Reading

Aspirin May Prolong Life in PIK3CA-Mutated Colorectal Cancers (November 6, 2012)

Daily aspirin use improves survival among patients with mutated-PIK3CA colorectal cancer, according to the results of a study published in the New England Journal of Medicine. Colorectal cancer remains the second leading cause of cancer-related death... Continue Reading

Adjuvant Therapy May Offer Survival Benefit in Older Patients with Colorectal Cancer (September 11, 2012)

Adjuvant chemotherapy appears to offer a survival benefit to patients aged 75 years or older who have surgically resected colorectal cancer, according to the results of a study published in the Journal of Clinical Oncology. Colorectal cancer is the second... Continue Reading

Rectal Cancer Patients May Benefit from Higher Dose of Preoperative Radiation (October 12, 2011)

Among rectal cancer patients treated with chemotherapy and radiation therapy prior to surgery, providing a higher dose of radiation therapy (50 Gy rather than 45 Gy) may reduce the risk of cancer recurrence. These results were presented at the 53rd Annual... Continue Reading

African Americans Most Willing to Exhaust Resources for Life-Extending Care (May 5, 2011)

African Americans who are diagnosed with lung or colorectal cancer may be more willing than Whites to expend all personal financial resources in order to extend their lives. Other minority groups also appear more likely than Whites to use personal resources.... Continue Reading

More Stages I-III Rectal Cancer